Detection of Micrometastatic Disease in Bone Marrow: Is It Ready for Prime Time?

Janni, Wolfgang; Rack, Brigitte; Lindemann, Kristina; Harbeck, Nadia

doi:10.1634/theoncologist.10-7-480

Cited by 17 publications

(13 citation statements)

References 125 publications

(127 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the advent of immunohistochemistry and molecular assays such as the polymerase-chain reaction, there is increasing evidence in the identification of small numbers of isolated tumor cells in the bone marrow below the limit of detection by conventional histopathologic evaluation. Although these bone marrow ''micrometastases'' can be identified in 30-40% of patients with malignancy, their prognostic significance remains controversial (71)(72)(73).…”

Section: Nonhematopoietic Tumorsmentioning

confidence: 99%

Bone marrow aspirate and biopsy: a pathologist's perspective. II. interpretation of the bone marrow aspirate and biopsy

Riley

Williams

Ross

et al. 2009

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Bone marrow examination has become increasingly important for the diagnosis and treatment of hematologic and other illnesses. Morphologic evaluation of the bone marrow aspirate and biopsy has recently been supplemented by increasingly sophisticated ancillary assays, including immunocytochemistry, cytogenetic analysis, flow cytometry, and molecular assays. With our rapidly expanding knowledge of the clinical and biologic diversity of leukemia and other hematologic neoplasms, and an increasing variety of therapeutic options, the bone marrow examination has became more critical for therapeutic monitoring and planning optimal therapy. Sensitive molecular techniques, in vitro drug sensitivity testing, and a number of other special assays are available to provide valuable data to assist these endeavors. Fortunately, improvements in bone marrow aspirate and needle technology has made the procurement of adequate specimens more reliable and efficient, while the use of conscious sedation has improved patient comfort. The procurement of bone marrow specimens was reviewed in the first part of this series. This paper specifically addresses the diagnostic interpretation of bone marrow specimens and the use of ancillary techniques.

show abstract

Section: Nonhematopoietic Tumorsmentioning

confidence: 99%

Bone marrow aspirate and biopsy: a pathologist's perspective. II. interpretation of the bone marrow aspirate and biopsy

Riley

Williams

Ross

et al. 2009

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…The recognition that tumor cells may disseminate at very early stages of BC (2) and that metastatic disease may recur many years after initial therapy strongly suggests that disseminated cells can survive for extended periods in a growth-arrested state (3).…”

Section: Introductionmentioning

confidence: 99%

Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells

et al. 2013

View full text Add to dashboard Cite

“…The early detection of such minimal amounts of residual or recurrent malignoma cells has been shown to be a major prognostic factor for adult and childhood acute lymphoblastic leukemia (1,2). Among solid tumors, the clinical relevance of minimal residual disease (MRD) during and after therapy has been most extensively studied in breast cancer patients (3,4). Smaller studies report a significant impact on prognosis for minimal numbers of tumor cells or tumor cell DNA detected in the BM or PB, respectively, for different types of nonhematological malignancies (3,5,6).…”

Section: Introductionmentioning

confidence: 99%

Detection of human tumor cells by amplicon fusion site polymerase chain reaction (AFS-PCR)

Weber¹,

Taube²,

Starke³

et al. 2011

J. Clin. Invest.

View full text Add to dashboard Cite

Reliable diagnostic strategies for individuals with cancer demand practical methods for highly sensitive and specific detection of tumor cells. Amplification of genomic regions that include putative oncogenes is common in tumor cells of various types. Genomic array platforms offer the opportunity to identify and precisely map amplified genomic regions (ampGRs). The stable existence of these tumor cell-specific genomic aberrations during and after therapy, in theory, make ampGRs optimal targets for cancer diagnostics. In this study, we mapped ampGRs around the proto-oncogene MYCN of human neuroblastomas using a high-resolution tiling array (HR-TA). Based on the HR-TA data, we were able to precisely describe the telomeric and centromeric borders of the ampGRs and deduce virtual fusion sites of the joined ampGRs (amplicon fusion sites [AFSs]). These AFSs served as blueprints for the subsequent design of AFS bridging PCR assays (AFS-PCRs). Strikingly, these assays were absolutely tumor cell specific and capable of detecting 1 tumor cell in 1 × 10 6 to 8 × 10 6 control cells. We successfully proved the in vivo practicability of AFS-PCR by detecting and quantifying the specific AFS DNA of human MYCN-amplified neuroblastomas in the patients' corresponding peripheral blood and bone marrow samples. Thus, we believe AFS-PCR could become a powerful and nevertheless feasible personalized diagnostic tool applicable to a large number of cancer patients, including children with MYCN-amplified neuroblastomas.

show abstract

Detection of Micrometastatic Disease in Bone Marrow: Is It Ready for Prime Time?

Abstract: Minimal residual disease (MRD), or isolated tumor cells (ITCs

Cited by 17 publications

References 125 publications

Bone marrow aspirate and biopsy: a pathologist's perspective. II. interpretation of the bone marrow aspirate and biopsy

Bone marrow aspirate and biopsy: a pathologist's perspective. II. interpretation of the bone marrow aspirate and biopsy

Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells

Detection of human tumor cells by amplicon fusion site polymerase chain reaction (AFS-PCR)

Contact Info

Product

Resources

About